Katherine Stueland

CEO Katherine Stueland sold 10,501 shares at avg $60.77 for $638,104.42 on 2026-06-16, retaining 104,372 shares + 56,250 RSUs

Katherine Stueland, Chief Executive Officer of GeneDx Holdings Corp., executed 3 separate sales totaling 10,501 shares for $638,104.42 at an average price of $60.77 on 2026-06-16. The sales reduced her non-derivative holdings by 9.1% while she retains 104,372 shares plus 56,250 RSUs in restricted stock. The transaction occurred when the stock trades at $59.01, down 65.5% from its 52-week high of $170.87 but up 40.1% over the prior 30 days, suggesting the sales may reflect opportunistic price recovery rather than distress. Notably, Stueland's 5 prior sales at WGS on 2026-03-26 each generated positive 30-day returns (ranging from 5.1% to 11.8%), yet her broader cross-ticker sell history shows a 100% well-timed rate at the 90-day mark—a pattern worth monitoring if sustained outcomes at this ticker diverge.

GeneDx CEO Katherine Stueland sold 46,933 shares (33.9% stake reduction) for $2,964,841.37 across 5 sales on 2026-03-26 as stock down 64.4% from high.

Katherine Stueland, GeneDx CEO, executed 5 separate sales totaling 46,933 shares for $2,964,841.37 on 2026-03-26, reducing her holdings by 33.9% from 138,447 to 91,514 shares. The sales occurred at an average price of $63.17, while the stock currently trades at $59.61—down 64.4% from its 52-week high of $167.52 and down 25.2% over the prior 30 days. The company is unprofitable (latest quarter net income of $-7,635,000.00 despite quarterly revenue of $116,743,000.00) and trades at a steep P/E multiple of 52.29. The timing of this large, multi-tranche CEO liquidation during a severe drawdown and following recent sell activity on 2026-03-04 and 2026-03-16 warrants attention, though no contemporaneous 10b5-1 plan is disclosed.

CEO Katherine Stueland sold 17,179 shares ($1.3M) at $76.80 avg on 2026-03-16; stock down 54.9% from 52-week high, unprofitable

Katherine Stueland, Chief Executive Officer of GeneDx Holdings Corp., executed 3 separate sales totaling 17,179 shares (17.2K shares) for $1,319,290.53 ($1.3M) on 2026-03-16 at prices ranging from $76.35 to $77.94, reducing her holdings by 22.7%. The timing is noteworthy: the stock is currently trading 54.9% below its 52-week high of $167.52, down 16.2% in the past 30 days and 44.5% over 90 days, while the company remains unprofitable (net income $-7.6M in the latest quarter despite 40% revenue growth). Stueland's prior trades at this ticker show a 100% well-timed rate at the 90-day mark (2 of 2 measurable prior sells preceded declines of 24.8% and 21.3% respectively), suggesting pattern recognition in sell timing at WGS specifically. The sale occurs against a backdrop of elevated valuation (P/E 66.23) despite persistent losses and recent sharp price deterioration, warranting examination of whether the CEO's reduction signals management's own assessment of risk.

GeneDx CEO Stueland sells 25,459 shares for $2.0M at blended avg $78.61 amid 51% decline from 52-week high.

Katherine Stueland, CEO of GeneDx Holdings (WGS), executed 3 separate sales totaling 25,459 shares for $2,001,370.72 on 2026-03-04 at prices ranging from $77.63 to $79.25. The sales reduced her holding from 64,142 shares to 38,683 shares, a -39.7% reduction in pre-transaction holdings. The transaction occurred at a time when the stock has fallen -51.0% from its 52-week high of $167.52 and is down -13.9% over the past 30 days, signaling a material deterioration in stock value since acquisition. Within the same ticker at WGS, Stueland's 5 prior trades (all conducted on 2025-12-16) showed consistent negative 30-day performance ranging from -22.0% to -24.8%, suggesting recent trades have preceded near-term declines. The company remains unprofitable (net income $-7,635,000.00 for the latest quarter) despite 40% annual revenue growth, and at current market price of $82.00, the stock is trading far below the execution price, indicating the sale occurred well before the price further eroded.

GeneDx CEO Katherine Stueland sold 10,857 shares (43.3% of pre-transaction holdings) across 11 separate transactions on 2025-12-16 for $1.6M.

Katherine Stueland, GeneDx CEO, executed 11 separate sales on 2025-12-16 totaling 10,857 shares for $1,562,185.19, reducing her holdings from 25,094 shares to 14,237 shares. The transactions ranged from $138.93 to $150.75 per share, with a blended average of $143.89—notably above the current price of $136.32. At the same-ticker level, Stueland's four measurable sales on 2025-09-30 posted positive 30-day returns ranging from +15.7% to +25.1%, indicating the stock rose after those prior sales, yet none of her prior WGS trades have reached the 90-day measurement window. Against her cross-ticker track record, her 90-day well-timed sell rate stands at 36.36%, showing mixed historical execution. The company remains unprofitable (net income $-7.6M against revenue $116.7M) despite strong revenue growth of +50.8% year-over-year, and the stock is -18.6% from its 52-week high of $167.52.

GeneDx CEO Katherine Stueland sold 3.6K shares at $159.28 for $579.6K; stock now down -7.2% from 52-week high despite +11.0% 30-day gain.

Katherine Stueland, CEO of GeneDx Holdings (WGS), sold 3,639 shares at $159.28 on 2025-12-09, reducing her holdings by 36.5% from 9,983 to 6,344 shares. The sale occurred near the 52-week high ($167.52), with the current price at $155.37. Across her cross-ticker track record of 20 prior open-market sells, Stueland has achieved a 45.45% well-timed rate at the 90-day mark, though her same-ticker history at WGS shows 5 prior sells from September 2025 with positive 30-day returns (all +17.6% to +25.1%) but no measurable 90-day outcomes yet. GeneDx remains unprofitable (full-year net income negative, most recent quarter: -$7.6M) despite strong revenue growth of 50.8% year-over-year and a substantial market cap of $4.5B, creating a valuation profile with a P/E of 2219.57 that warrants investor scrutiny of profitability trajectory and cash burn sustainability.

GeneDx CEO Stueland sells 12,858 shares for $1.39M across 8 trades; holds only 1,720 shares post-sale (88.2% reduction)

Katherine Stueland, Chief Executive Officer of GeneDx, executed 8 separate sales totaling 12,858 shares for $1,390,911.39 on 2025-09-30. This represents a -88.2% reduction in her holdings (from 14,578 to 1,720 shares), leaving her with minimal equity stake in the company she leads. Across her 5 prior same-ticker trades at WGS, none were well-timed at the 90-day mark (all generated positive 90-day returns, meaning the stock rose after each sale), establishing a pattern of selling before gains accelerated. The current stock price of $113.44 sits 12.4% below its 52-week high of $132.54 and the blended sale prices averaged $108.17, positioning this liquidation in a near-peak valuation window. The company trades at a P/E of 2268.80 despite positive quarterly fundamentals (revenue $102.7M, net income $10.8M, annual growth +50.8%) but has posted negative full-year net income, creating a valuation disconnect that may contextualize the magnitude of this stake reduction.

CEO Katherine Stueland sold 10,501 shares (41.9% of holdings) at $121.47; stock now at $130.71 (+8.3% in 30d).

Katherine Stueland, CEO of GeneDx Holdings Corp., sold 10,501 shares on 2025-09-16 at $121.47, reducing her holdings from 25,079 shares to 14,578 shares—a net reduction of 41.9% of her pre-transaction position. The stock has appreciated $130.71 today, representing an 8.3% gain over the 30-day period following the sale and trading near its 52-week high of $132.54. Within the context of her same-ticker trading history, her prior two measurable sales at WGS showed positive 90-day returns (+91.4% and +2.4%), indicating those sales preceded market rallies rather than declines, whereas her cross-ticker track record shows a 70.59% well-timed rate across 20 prior sells. The company is currently unprofitable on a full-year basis despite strong revenue growth of 50.8% year-over-year and has an elevated P/E of 2614.20, reflecting outsized market valuation relative to near-term earnings. This sale by the CEO reduces her direct equity stake significantly at a juncture when the stock is near historic highs and fundamentals remain mixed.

GeneDx CEO Stueland sells 9,657 shares for $878,180.62, divesting 66.2% of holdings at blended avg $90.94

Katherine Stueland, CEO of GeneDx Holdings (WGS), executed 3 separate sales totaling 9,657 shares for $878,180.62 on 2025-07-01, reducing her post-transaction holdings to 4,940 shares from 14,597 shares—a 66.2% reduction in stake. The company trades at $91.61 currently, down 21.7% from its 52-week high of $116.97, despite a 25.8% 30-day gain and 14.5% 90-day gain. GeneDx is unprofitable (net income of $-6,529,000.00 over the latest full fiscal year) with revenue of $87,115,000.00 in the latest quarter and 50.8% annual revenue growth; the market cap is $2,613,926,818.44. Stueland's cross-ticker track record shows a 100.00% well-timed rate on 20 prior sells (avg 90d return -14.0%), but her 5 prior WGS-specific trades show deteriorating execution at this ticker, with 4 sells on 2025-04-09 posting 30-day returns ranging from -39.2% to -27.1% and 0 of her prior sells at WGS achieving well-timed outcomes by the 90-day measure. The substantial reduction in CEO equity stake warrants attention given the unprofitable state and the divergence between her demonstrated cross-ticker timing acumen and her recent execution specifically at this holding.

CEO Katherine Stueland sold 10,501 shares at $64.77; stock down 44.9% from 52-week high, down 33.4% in 90 days

Katherine Stueland, Chief Executive Officer of GeneDx Holdings Corp. (WGS), sold 10,501 shares for $680,181.27 on 2025-06-16, reducing her position by 41.8% to 14,597 shares. The sale occurred at $64.77 while the stock now trades at $64.43, down 33.4% over the past 90 days and 44.9% from its 52-week high of $116.97. This represents a significant reduction in the CEO's direct equity stake at a price point substantially below recent highs, even though the stock is currently near the transaction price. The company reported $87.1M in quarterly revenue with strong 50.8% annual growth, but remains unprofitable with a $-6.5M net loss, indicating the decline may reflect broader uncertainty despite revenue traction. Her prior five trades at WGS all occurred on 2025-04-09 and showed negative 30-day returns ranging from -27.1% to -39.2%, establishing a pattern of sells preceding short-term weakness at this ticker.